MiMedx Showcases Innovations at SAWC Fall Meeting
MiMedx Group, Inc. (NASDAQ: MDXG) has announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting, a premier event in the advanced wound care sector. This meeting serves as a platform for industry leaders and healthcare professionals to share groundbreaking research and clinical practices that enhance patient outcomes.
Insightful Research Presentation
At the heart of MiMedx's presentation is their comprehensive allograft portfolio designed to support various clinical applications in wound care. Dr. John R. Harper, the Chief Scientific Officer of MiMedx, expressed excitement over their contributions to the understanding of placental tissue, emphasizing its benefits in wound healing. The company's commitment to innovation was evident as they prepared to share updates on their research focusing on crucial aspects of the wound healing process, particularly inflammation and epithelialization.
Symposium Highlights
The SAWC Fall meeting features numerous events where MiMedx plans to demonstrate its leadership and dedication to advancing wound care practices. On October 3, they are hosting a sponsored lunch symposium titled, 'Wound Care Evolution: Patients Change, Practices Change, Payors Change: Providers Adapt.' This event will gather experts to discuss the shifting landscape of wound care and the vital need for healthcare professionals to adapt to these changes in patient demographics and treatment methodologies.
Hands-On Skills Lab
In addition to the symposium, MiMedx will facilitate a hands-on skills lab titled, 'Overcoming Challenges in Assessing and Managing Lower Extremity Wounds: Hands-On Workshop.' This engaging session aims to equip attendees with practical skills through product demonstrations that include debridement technologies, compression therapy, and other innovative treatment techniques for lower extremity wounds.
Accepted Poster Presentations
MiMedx is proud to present seven clinical and scientific posters at the meeting, highlighting their ongoing research efforts. These presentations encapsulate significant findings from various studies on wound care:
Clinical Research Highlights
- Investigation of Chronic Pressure Injuries using Lyophilized Human Amnion/Chorion Membrane.
- Analysis of Dehydrated Human Amnion Chorion Membrane for Reconstruction Following Mohs Surgery.
- Patient Survey Study on Hard-to-Heal Wounds.
- Impact of Medicaid Status on Venous Leg Ulcer Outcomes.
- Exploration of Pyoderma Gangrenosum and the Role of Dehydrated Human Amnion/Chorion Membrane.
Scientific Research Contributions
- Study on Macrophage Response Modulation during Wound Healing via Lyophilized Human Amnionic Membrane.
- Tri-Layer Amniotic Membrane Allografts' Role in Promoting Re-Epithelialization.
About MiMedx
MiMedx continues to be at the forefront of innovation in the healthcare sector, particularly in the field of wound care. With a steadfast dedication to developing advanced solutions for chronic and complex wounds, the company aims to improve the quality of life for patients globally. Their strategic focus is rooted in relentless innovation, ensuring that they remain a trusted provider of healing solutions.
Contact Information
For more details about MiMedx and their offerings in the wound care landscape:
Contact:
Matt Notarianni
Investor Relations
470-304-7291
Email: mnotarianni@mimedx.com
Frequently Asked Questions
What is MiMedx showcasing at the SAWC Fall Meeting?
MiMedx is showcasing their allograft portfolio and recent clinical research developments aimed at enhancing wound healing.
When is the SAWC Fall Meeting?
The SAWC Fall Meeting takes place from October 2-5.
What type of sessions is MiMedx hosting during the symposium?
MiMedx is hosting a symposium and a hands-on skills lab focused on advanced wound care techniques.
How does MiMedx contribute to the field of wound care?
MiMedx advances the field through innovative product offerings and significant clinical research initiatives.
How can I contact MiMedx for more information?
You can contact MiMedx Investor Relations via email at mnotarianni@mimedx.com.
